Literature DB >> 30858572

Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition.

Tomomi Toubai1, Hideaki Fujiwara1, Corinne Rossi1, Mary Riwes1, Hiroya Tamaki2, Cynthia Zajac1, Chen Liu3, Anna V Mathew4, Jaeman Byun4, Katherine Oravecz-Wilson1, Ikuo Matsuda2, Yaping Sun1, Daniel Peltier1, Julia Wu1, Jiachen Chen1, Sergey Seregin1, Israel Henig1, Stephanie Kim1, Stuart Brabbs1, Subramaniam Pennathur4, Grace Chen5, Pavan Reddy6.   

Abstract

Host NOD-like receptor family pyrin domain-containing 6 (NLRP6) regulates innate immune responses and gastrointestinal homeostasis. Its protective role in intestinal colitis and tumorigenesis is dependent on the host microbiome. Host innate immunity and microbial diversity also play a role in the severity of allogeneic immune-mediated gastrointestinal graft-versus-host disease (GVHD), the principal toxicity after allogeneic haematopoietic cell transplantation. Here, we examined the role of host NLRP6 in multiple murine models of allogeneic bone marrow transplantation. In contrast to its role in intestinal colitis, host NLRP6 aggravated gastrointestinal GVHD. The impact of host NLRP6 deficiency in mitigating GVHD was observed regardless of co-housing, antibiotic treatment or colonizing littermate germ-free wild-type and NLRP6-deficient hosts with faecal microbial transplantation from specific pathogen-free wild-type and Nlrp6-/- animals. Chimaera studies were performed to assess the role of NLRP6 expression on host haematopoietic and non-haematopoietic cells. The allogeneic [B6Ly5.2 → Nlrp6-/-] animals demonstrated significantly improved survival compared to the allogeneic [B6Ly5.2 → B6] animals, but did not alter the therapeutic graft-versus-tumour effects after haematopoietic cell transplantation. Our results unveil an unexpected, pathogenic role for host NLRP6 in gastrointestinal GVHD that is independent of variations in the intestinal microbiome and in contrast to its well-appreciated microbiome-dependent protective role in intestinal colitis and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30858572      PMCID: PMC6689241          DOI: 10.1038/s41564-019-0373-1

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  1 in total

1.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

  1 in total
  17 in total

Review 1.  Microbiome-intestine cross talk during acute graft-versus-host disease.

Authors:  Hind Rafei; Robert R Jenq
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 2.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 3.  The NLRP6 inflammasome in health and disease.

Authors:  Laxman Ghimire; Sagar Paudel; Liliang Jin; Samithamby Jeyaseelan
Journal:  Mucosal Immunol       Date:  2020-01-27       Impact factor: 7.313

Review 4.  Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India.

Authors:  Ajay Sharma; Biju George; Chezian Subhash; Dinesh Bhurani; Dharma Choudhary; Jose Easow; Joseph John; Lalit Kumar; Neeraj Sidharthan; Pankaj Malhotra; Rayaz Ahmed; Revathy Raj; Rahul Bhargava; Satya Prakash Yadav; Sharat Damodar; Soniya Nityanand; Sunil Bhat; Tapan Saikia; Tulika Seth; Velu Nair; Vikram Mathews
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-21       Impact factor: 0.900

Review 5.  Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.

Authors:  Suze A Jansen; Edward E S Nieuwenhuis; Alan M Hanash; Caroline A Lindemans
Journal:  Mucosal Immunol       Date:  2022-06-02       Impact factor: 8.701

Review 6.  Therapeutic implications of inflammasome in inflammatory bowel disease.

Authors:  Vishal Khatri; Ramaswamy Kalyanasundaram
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.834

7.  Targeting the Aryl Hydrocarbon Receptor With Indole-3-Aldehyde Protects From Vulvovaginal Candidiasis via the IL-22-IL-18 Cross-Talk.

Authors:  Monica Borghi; Marilena Pariano; Valentina Solito; Matteo Puccetti; Marina M Bellet; Claudia Stincardini; Giorgia Renga; Carmine Vacca; Federica Sellitto; Paolo Mosci; Stefano Brancorsini; Luigina Romani; Claudio Costantini
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

8.  Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis.

Authors:  Amy I Yu; Lili Zhao; Kathryn A Eaton; Sharon Ho; Jiachen Chen; Sara Poe; James Becker; Allison Gonzalez; Delaney McKinstry; Muneer Hasso; Jonny Mendoza-Castrejon; Joel Whitfield; Charles Koumpouras; Patrick D Schloss; Eric C Martens; Grace Y Chen
Journal:  Cell Rep       Date:  2020-04-07       Impact factor: 9.423

Review 9.  Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease.

Authors:  Stephanie Kim; Pavan Reddy
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

10.  ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota.

Authors:  Sup Kim; June-Young Lee; Seul Gi Shin; Jin Kyung Kim; Prashanta Silwal; Young Jae Kim; Na-Ri Shin; Pil Soo Kim; Minho Won; Sang-Hee Lee; Soo Yeon Kim; Miwa Sasai; Masahiro Yamamoto; Jin-Man Kim; Jin-Woo Bae; Eun-Kyeong Jo
Journal:  Autophagy       Date:  2020-12-15       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.